造口周围坏疽性脓皮病对 risankizumab 治疗有反应。

Peristomal Pyoderma Gangrenosum Responding to Risankizumab.

机构信息

In Miami, Florida, Maximillian A. Weigelt, MD, is Clinical Research Fellow, Dr Phillip Frost Department of Dermatology & Cutaneous Surgery University of Miami Miller School of Medicine; and Robert S. Kirsner, MD, PhD, is Chairman and Harvey Blank Professor, Dr Phillip Frost Department of Dermatology & Cutaneous Surgery, Professor of Public Health Sciences, University of Miami Miller School of Medicine, and Director, University of Miami Hospital and Clinics Wound Center. Acknowledgments: This manuscript describes off-label product use: risankizumab for pyoderma gangrenosum. The authors have disclosed no financial relationships related to this article. Submitted May 6, 2020; accepted in revised form June 19, 2020.

出版信息

Adv Skin Wound Care. 2021 Jun 1;34(6):327-329. doi: 10.1097/01.ASW.0000744324.59877.df.

DOI:10.1097/01.ASW.0000744324.59877.df

PMID:33979822

Abstract

Evidence to support available therapies for pyoderma gangrenosum (PG) is limited. Many patients do not respond to topical therapies such as tacrolimus or topical steroids. Currently favored oral systemic treatments (eg, cyclosporine and steroids) achieve complete remission in only 50% of patients and have unfavorable adverse effect profiles. There is a growing body of evidence to support biologic agents for the treatment of PG, but their exact role remains unclear. Here the authors present a patient with peristomal PG, the first reported case of PG responding to treatment with risankizumab, an anti-interleukin 23 monoclonal antibody. Risankizumab may represent an effective and relatively safe treatment for PG that merits additional exploration in prospective, controlled studies.

摘要

支持治疗坏疽性脓皮病 (PG) 的现有疗法的证据有限。许多患者对他克莫司或局部类固醇等局部治疗无反应。目前受青睐的口服全身性治疗（例如环孢素和类固醇）仅使 50%的患者获得完全缓解，并且具有不良的不良反应谱。越来越多的证据支持生物制剂治疗 PG，但它们的确切作用仍不清楚。在这里，作者介绍了一位患有肠造口周围 PG 的患者，这是首例报告的 PG 对白细胞介素 23 单克隆抗体 risankizumab 治疗有反应的病例。Risankizumab 可能是一种有效且相对安全的 PG 治疗方法，值得在前瞻性对照研究中进一步探索。